American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
Trypanosoma cruzi retinitis following donor-derived Chagas disease after heart transplantation.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kraker Jessica A, Mitchell Charlotte, Saladi Nikita, Wesalo Joshua, Kesav Natasha, Casias Michael, Chuzi Sarah E, Henao-Martínez Andrés F, Beatty Norman L, Campbell Thomas B, Montague Brian, Armstrong Wendy, Scruggs Brittni A, Janetos Timothy, Gill Manjot K, Lam Matthew, Arguinchona Lauren, Reddy Amit K, Chiu Chia-Yu
Аннотация
Donor-derived Trypanosoma cruzi infection is a recognized complication of solid organ transplantation, but ocular involvement has never been reported. We described a case of necrotizing retinitis due to T. cruzi in a heart transplant recipient. A 62-year-old man developed unexpected donor-derived Chagas disease 3 months posttransplant and completed a 12-week course of nifurtimox with near-complete clearance of parasitemia. Thirty-eight days after nifurtimox discontinuation, he presented with progressive unilateral vision loss and clinical findings consistent with acute retinal necrosis. Vitreous biopsy with pan-pathogen polymerase chain reaction was negative for viral etiologies but confirmed T. cruzi. Despite systemic benznidazole therapy and clearance of blood parasitemia, intraocular disease progressed, ultimately attempting a salvage adjunctive intravitreal therapy with voriconazole. Ocular inflammation improved, but vision remained limited to light perception. This case underscores the need for continued clinical vigilance for late complications of Chagas disease in transplant recipients. Universal screening for donors with T. cruzi should be considered in future practice, pending the identification of the most appropriate assay, improved accessibility to such assays, and logistical challenges faced by individual organ procurement organizations.